Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease

Lung

Volumn 191, Issue 5, 2013, Pages 523-530

  Miravitlles, Marc ^a,b   García Polo, Cayo ^c   Domenech, Adolfo ^d   Villegas, Gustavo ^e   Conget, Francisco ^f   De La Roza, Cristian ^g  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL TORRECÁRDENAS   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g Sant Joan Despi   (Spain)

Author keywords

Antibiotics; COPD; Costs; Exacerbation; Hospitalization

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CEFDITOREN; CEFUROXIME; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; LEVOFLOXACIN; MOXIFLOXACIN; MUCOLYTIC AGENT; XANTHINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84884812150     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9487-z     Document Type: Article

References (35)

1. Decramer M, Janssens W, Miravitlles M (2012) Chronic obstructive pulmonary disease. Lancet 379:1341-1351
2. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418-1422
3. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa JF et al (2004) Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax 59:387-395
4. Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A et al (2012) Predictors of adverse outcome in patients hospitalised for exacerbation of COPD. Respiration 84:17-26
5. Burrows B, Bloom JW, Traver GA, Cline MG (1987) The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 317:1309-1314
6. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ et al (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27:188-207
7. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R (1999) Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 21:576-591
8. Miravitlles M, Murio C, Guerrero T, Gisbert R, DAFNE Study Group (2002) Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121:1449-1455
9. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R (1995) Acute infective exacerbations of chronic bronchitis. QJM 88:61-68
10. Adams SG, Melo J, Luther M, Anzueto A (2000) Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117:1345-1352
11. Miravitlles M, Murio C, Guerrero T, DAFNE Study Group (2001) Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 17:928-933
12. Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D et al (2012) Moxifloxacin vs amoxicillin/clavulanic acid in acute exacerbations of COPD: MAESTRAL study results. Eur Respir J 40:17-27
13. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al (2012) Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 48:247-257
14. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS (1992) Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 15:S62-S88
15. Spanish National Pharmacy. http://www.msc.es/profesionales/nomenclator. do. Accessed Oct 2012
16. Oblikue Consulting, Barcelona SL, Spain. http://www.oblikue.com/ bddcostes/. Accessed Oct 2012 (property of R. Gisbert and M. Brosa)
17. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297-1303
18. Seneff MG, Douglas P, Wagner P et al (1995) Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbations of chronic obstructive pulmonary disease. JAMA 274:1852-1857
19. Soler-Cataluña JJ, Martinez-Gracía MA, Roman Sánchez P, Salcedo E, Navarro M, Ochando R (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925-931
20. Vilkman S, Keistinen T, Tuuponen T, Kivelä SL (1997) Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 64:281-284
21. Miravitlles M, Murio C, Guerrero T, Gisbert R, DAFNE Study Group (2003) Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 123:784-791
22. Jacobson L, Hertzman P, Löfdahl CG et al (2000) The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 94:247-255
23. Wilson L, Devine EB, So K (2000) Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94:204-213
24. Oostenbrink JB, Rutten-van Mölken MPMH (2004) Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 98:883-891
25. Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiñá M (2001) The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 37:375-381
26. García-Polo C, Alcázar-Navarrete B, Ruiz-Iturriaga LA, Herrejón A, Ros-Lucas JA, García-Sidro P et al (2012) Factors associated with high resource utilisation among COPD patients. Respir Med 106:1734-1742
27. Mapel DW, McMillan GP, Frost FJ, Hurley JS, Picchi MA, Lydick E et al (2005) Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med 99:1325-1333
28. Alcázar B, García-Polo C, Herrejón A, Ruiz LA, de Miguel J, Ros JA et al (2012) Factors associated with hospital admission for exacerbation of chronic obstructive pulmonary disease. Arch Bronconeumol 48:70-76
29. Miravitlles M, Monsó E, Mensa J, Aguarón Pérez J, Barberán J, Bárcena Caamaño M et al (2008) Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol 44:100-108
30. Miravitlles M, Sicras A, Crespo C, Cuesta M, Brosa M, Galera J et al (2013) Costs of COPD in relation to compliance with guidelines. A study in the primary care setting. Ther Adv Respir Dis 7:139-150
31. Anzueto A, Miravitlles M (2010) Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med 104:1396-1403
32. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J (2005) Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 99:955-965
33. Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K (2012) Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD. Respir Med 106:1258-1267
34. Llor C, Serra N, Hernández S, Moragas A, Hernández M, Bayona C et al (2009) The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J Antimicrob Chemother 63:396-399
35. Llor C, Naberan K, Cots JM, Molina J, Miravitlles M (2004) Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care centers. Int J Clin Pract 58:937-944